Whetstone Capital Increases Stake in Health Catalyst to 4.5% via Long Call Options

Key Facts

Amid growing interest from investment funds in value opportunities within the digital healthcare sector, Whetstone Capital Advisors has strengthened its market presence. The firm, along with David Atterbury, disclosed a 4.5% beneficial ownership stake in Health Catalyst (HCAT), amounting to 3,285,690 shares. The acquisition was executed using approximately $7.83 million in working capital, involving a combination of common stock and long call options expiring in December 2026.

This move comes as institutional investors seek opportunities in companies showing signs of operational efficiency improvements, with HCAT being a prominent player in healthcare data analytics. Compared to peers, companies like Veeva Systems and R1 RCM have seen mixed performance recently due to inflationary pressures and financing costs. Per market data, increased institutional ownership often precedes a re-rating of assets within the mid-cap technology sector.

Regarding market performance, HCAT closed at $1.75 (close June 8, 2026), trading within a session range of $1.71 to $1.98. Traders are currently monitoring resistance levels near the $2.00 mark, supported by the positive momentum from Whetstone's entry. Looking ahead, upcoming US inflation data on June 10 may impact risk appetite in the growth sector, potentially influencing the stock's short-term trajectory.